Soluble mediators, e.g. cytokines, chemokines and growth factors, are acknowledged as key players in the pathophysiology of osteoarthritis (OA) (1, 2). However, a widespectrum screening of such mediators in the joint environment is currently lacking.
Brief report
A control group of knee synovial fluid samples (n=16) were collected from post mortem donors within 24 hours after death. Control donors had no history of OA, other joint pathology and possessed macroscopic healthy cartilage. OA synovial fluid samples (n=18) were collected during total knee arthroplasty. All OA patients were diagnosed according to the ACR criteria for OA (3) . Exclusion criteria were rheumatoid arthritis (RA) or infection. Synovial fluid samples were centrifuged at 3000 rpm for 3 minutes to spin down any cells or debris. The supernatant was stored at -80 °C until further analysis. The control synovial fluid samples were stored for 1 to 10 years and OA synovial fluid samples were stored for 1 to 3 years. None of the samples had ever been thawed before. Collection of the synovial fluid was done according to the Medical Ethical regulations of the University Medical Centre Utrecht and according to the guideline 'good use of redundant tissue for clinical research' constructed by the Dutch Federation of Medical Research Societies on collection of redundant tissue for research. As according to these guidelines, no information about the patients' characteristics could be obtained. Gender and age information was available for limited donors. Control donors had an average age of 39.6 ± 9.3 and consisted of 55% female. OA donors had an average age of 69.9 ± 7.9 and consisted of 64 % female.
Due to the limited availability these data could not be linked to any of the outcomes.
Two hundred µl of each of the OA synovial fluid samples was pre-treated with 20 µl of hyaluronidase (Sigma, St, Louis, MO, USA; 10 mg/ml) for 15 min at 37 °C. Samples were spun down in a X-column (Corning, Amsterdam, Netherlands; Costar 8169). Finally, 150 µl of the synovial fluid sample was dissolved in 300 µl HPE-0.1375% Tween (Sanquin, Amsterdam, Netherlands). The pre-treated synovial fluid samples were used for all Multiplex ELISA assays mentioned below.
To determine a wide panel of soluble mediators the commercially available human inflammation 42-multiplex and the human adipokine 13-multiplex (Millipore, Bellirica, MA, USA) were used according to the manufacturer's protocol. Additionally, 12 different soluble mediators were measured with the Bio-Plex suspension system (Bio-Rad laboratories, Hercules CA, USA) as previously described (4) . The levels of cytokines in the synovial fluid samples were expressed as pg/ml. All samples were measured in the same plate and in duplo. Levels below the lower limit of quantification (LLOQ) were indicated as the value of the lowest point on the calibration curve divided by 2. The measured mediators are listed in table 1. Data are expressed as median ± interquartile range (IqR) as the data had a non-Gaussian distribution. IBM SPSS 20.0 software (IBM SPSS Inc. Chicago, IL, USA) was used for the statistical analysis.
For this study, a descriptive statistics approach was used for the interpretation of the data due to the limited sample size. A Mann Whitney-U test was used to assess differences between control and OA synovial fluid samples due to the predominantly non-Gaussian distribution of the data. As a descriptive statistic approach was used, values with a p-value less than 0.001 were considered significant. P values between 0.05 and 0.001 were considered borderline significant. No post-hoc correction for multiple testing was performed on the data, due to the descriptive approach.
PCA was performed to enable identification of clusters (i.e. components) of This is one of the first studies in which such a comprehensive profile of soluble mediators was measured in synovial fluid from (end-stage) OA patients and control donors. With regard to previous studies, the pattern of the mediator levels was found to be compatible for OA donors. However, in these studies a small panel of mediators was measured and the inclusion of control donors was lacking (e.g. (5)). Table 1 provides an overview of the measured levels of each mediator (median ± IqR). The majority of the soluble mediators could be detected in the synovial fluid samples of both control and OA donors. Of the 47 measured mediators, 5 mediators were present at significantly different levels in OA compared to control synovial fluid. The levels of the chemokines MDC, RANTES and IP-10, the growth factor PDGF-AA and the pro-inflammatory cytokine IL-6 were significantly higher in OA than in control synovial fluid (p < 0.001). In addition, levels of the adipokine leptin, the chemokine MIP-1β, and the pro-inflammatory cytokine sCD40L were higher and levels of the chemokine eotaxin and the growth factor G-CSF were lower in OA than in control synovial fluid, albeit all with borderline significance (p < 0.05). The PCA was performed to gain insight into the associations between individual mediators that were assessed. The PCA showed communalities > 0.3, which as such, were included in the analysis. PCA enabled identification of 6 clusters of interrelated mediators among the spectrum of 47 mediators ( Table 2) are associated with cartilage degeneration, synovial inflammation and bone changes (11) . Although in some in vivo animal models of OA, blocking IL-1 or TNFa gave promising results, this could not be validated in clinical studies (12) . Our results likewise do not support a prominent role for IL-1 and TNFα in end-stage OA patients.
Nonetheless, this does not exclude a role for IL-1 and TNFα in for example early OA, as OA has a heterogeneous character with multiple phenotypes.
For the interpretation of the data it should be mentioned that our results are based on a small sample size, due to donor availability, which were not paired on age, BMI and sex. Moreover, it should be taken into account that ex-vivo modifications cannot be excluded for the control donors as samples were taken after death. Also due to the small sample size, no further statistics were performed on the PCA to study differences between the clusters for OA and control synovial fluid samples.
Therefore this pilot dataset should be regarded as a reference and more extensive profiling studies are necessary to confirm these data.
In summary, this is the first study measuring a wide panel of mediators in the synovial fluid of both control and end-stage OA donors. Increased levels of mediators such as MDC, IL-6 and RANTES once more confirm involvement of inflammatory processes and might be associated with the influx of inflammatory cells in OA synovial tissue. In addition, the PCA indicated 6 clusters, which reflect different processes in the joint. Due to the small samples size no hard conclusions can be drawn.
Nonetheless, this pilot dataset provides a valuable reference for future experiments to study pathophysiological pathways, and to be useful in more extensive profiling studies for OA.
